Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2010-07-07 / Br. J. Haematol. 2010 Sep;150(5):554-64Advances in cellular therapy for the treatment of thyroid cancer
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2010-06-29 / J Oncol 2010;2010:179491Anti-HER2 vaccines: new prospects for breast cancer therapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2010-06-08 / Cancer Immunol. Immunother. 2010 Sep;59(9):1295-312INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
/in Dendritic Cells, International Publications, SCLC /von 2010-06-01 / Expert Opin Biol Ther 2010 Jun;10(6):983-91Dendritic cell vaccination as a treatment modality for mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2010-06-01 / Expert Rev Respir Med 2010 Jun;4(3):311-4Current status of immunological therapies for prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2010-05-01 / Curr Opin Urol 2010 May;20(3):241-6Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2
/in Dendritic Cells, Hypernephroma, International Publications /von 2010-05-01 / J. Immunother. 2010 May;33(4):425-34Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model
/in Dendritic Cells, International Publications, Prostate Cancer /von 2010-04-28 / J. Immunol. 2010 Jun;184(11):5954-8Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors
/in Dendritic Cells, International Publications /von 2010-04-20 / Semin. Immunol. 2010 Jun;22(3):173-82IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de